Wet age-related macular degeneration (wet AMD) is a progressive eye disease in which abnormal, fragile blood vessels grow ...
This is a quickly progressing field, according to Sarju Patel, MD, attending physician at Retinal Consultants of America. He has high expectations that advances from subtly tinted eyeglass lenses to ...
4D Molecular Therapeutics announced an acceleration in the timeline for its 4FRONT-1 Phase 3 trial data readout of the 4D-150 treatment for wet age-related macular degeneration (AMD), now expected in ...
Please provide your email address to receive an email when new articles are posted on . EYP-1901 and OTX-TKI have shown results similar to aflibercept 2 mg. Gene therapy is another type of treatment ...
EMERYVILLE, Calif., March 10, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (FDMT) (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and ...
– In AVONELLE-X, the largest long-term extension trial in wet AMD, disease control and durability were maintained over 4 years, with nearly 80% of patients on extended dosing by study end – – Over 60% ...
PulseSight Therapeutics completes patient enrolment in phase I trial of PST-611 to treat dry AMD/geographic atrophy: Paris, France Friday, January 23, 2026, 18:00 Hrs [IST] PulseS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results